Aposense

  • Home
  • About Us
    • Overview
    • Scientific president
    • Team
    • Board of directors
    • Intellectual property
  • Our Technology
  • SirVir
    • Aposense subsidiary in the field of respiratory viral infections
  • ATT-11T: Anti cancer pro-drug
    • On June 1st 2020 Aposense signed an agreement to license out the ATT-11T to Processa Pharmaceuticals
  • News
  • Contact Us


News

danapos
April 4 2021

Aposense and Bioasis Technologies Inc. Enter into a Research Collaboration

Aposense ltd, a highly innovative Israeli bio-pharmaceutical company, specializing in development of novel drugs, utilizing membrane electrical forces, is pleased to announce that it has formed a research collaboration with Bioasis Technologies Inc.
News
Read More
danapos
February 28 2021

SirVir Ltd., an Aposense subsidiary in the field of respiratory viral infections announce the fulfillment of a $14M milestone investment

SirVir Ltd., an Aposense subsidiary in the field of respiratory viral infections announce the fulfillment of a $14M milestone investment from Access Industries. Prior to this transaction SirVir reached its scientific milestone when generating safety and efficacy data against the SARS CoV2 on a non-human primates model
News
Read More
danapos
January 7 2021

Prof. Roger Kornberg mentions SirVir’s breakthrough results and applicability of the platform in an interview for Ynet.

The English translation of an interview on Ynet with Prof. Roger Kornberg the scientific president of Aposense and SirVir.
News
Read More
danapos
June 1 2020

Aposense enters into an out-licensing agreement with Processa Pharmaceuticals

Aposense announces that it entered into a license agreement with Processa Pharmaceuticals to license out its anti-cancer pro drug the ATT-11T.   Link to the PR  
News
Read More
danapos
April 26 2020

SirVir obtained positive results in pre-clinical experiment against COVID-19

SirVir, a subsidiary of Aposense, and the Israeli Institute for Biological Research (IIBR) announce positive results in their pre-clinical collaborative study in the eradication of the Corona virus COVID-19
News
Read More

Pages:

1 2 »
Aposense

Contact Us

Telephone: + 972.73.239.7600
Fax: +972.3.921.57.14
E-mail: info@aposense.com

Careers

  • משרת עוזר/ת מחקר

    24 Jan 2021

Latest news

  • Aposense and Bioasis Technologies Inc. Enter into a Research Collaboration

    4 Apr 2021

  • SirVir Ltd., an Aposense subsidiary in the field of respiratory viral infections announce the fulfillment of a $14M milestone investment

    28 Feb 2021

  • Prof. Roger Kornberg mentions SirVir’s breakthrough results and applicability of the platform in an interview for Ynet.

    7 Jan 2021

Aposense © 2021. Privacy Policy
  • Home
  • About Us
    ▼
    • Overview
    • Scientific president
    • Team
    • Board of directors
    • Intellectual property
  • Our Technology
  • SirVir
    ▼
    • Aposense subsidiary in the field of respiratory viral infections
  • ATT-11T: Anti cancer pro-drug
    ▼
    • On June 1st 2020 Aposense signed an agreement to license out the ATT-11T to Processa Pharmaceuticals
  • News
  • Contact Us
Skip to content
Open toolbar

Accessibility Tools

  • Increase Text
  • Decrease Text
  • Grayscale
  • High Contrast
  • Negative Contrast
  • Light Background
  • Links Underline
  • Readable Font
  • Reset